Phase II Trial of Pyrazoloacridine in Recurrent... : American Journal of Clinical Oncology (original) (raw)

Articles

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Resistant Ovarian Cancer

A Gynecologic Oncology Group Study

Plaxe, Steven C. M.D.; Blessing, John A. Ph.D.; Morgan, Mark A. M.D.; Carlson, John M.D.

From the Division of Gynecologic Oncology, University of California, San Diego (S.C.P.), San Diego, California; Gynecologic Oncology Group, Roswell Park Cancer Institute (J.A.B.), Buffalo, New York; Division of Gynecologic Oncology, University of Pennsylvania (M.A.M.); and Division of Gynecologic Oncology, Thomas Jefferson University Hospital (J.C.), Philadelphia, Pennsylvania, U.S.A.

Address correspondence to Dr. Steven C. Plaxe, Department of Reproductive Medicine, UCSD Medical Center, 402 Dickinson Street, San Diego, CA 92103-8433, U.S.A. Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107, U.S.A.

This study was supported by National Cancer Institute (NCI) grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

The following Gynecologic Oncology Group institutions participated in this study: Abington Memorial Hospital, Hospital of the University of Pennsylvania, Georgetown University Hospital, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, Indiana University Medical Center, Wake Forest University School of Medicine, The Albany Medical College of Union University, Tufts New England Medical Center, Rush-Presbyterian–St. Lukes Medical Center, State University of New York at Stony Brook, Pennsylvania Hospital, Cooper Hospital University Medical Center, Columbus Cancer Council, Fox Chase Cancer Center, Medical University of South Carolina, Thomas Jefferson University Hospital, and University of Toronto/Sunnybrook Regional Cancer Center.

Abstract

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.